Repurposing covalent EGFR/HER2 inhibitors for on-target degradation of human Tribbles 2 (TRIB2) pseudokinase
Daniel M Foulkes, Dominic P Byrne, Fiona P Bailey, Samantha Ferries, Claire E Eyers, Karen Keeshan, Safal Shrestha, Wayland Yeung, Natarajan Kannan, Carrow Wells, David H Drewry, William J Zuercher, Patrick A Eyers
The paper identifies EGFR/HER2 inhibitors that destabilize and degrade TRIB2 pseudokinase in cancer cells, suggesting potential for TRIB2-targeted therapies.
bioRxiv · Apr 20, 2018 · PreprintBiochemistry